Vector Science & Therapeutics Files Provisional Patent for Novel Microneedle Catheter Platform for Intratumoral Drug Delivery

Platform Integrates Three Research Modalities Targeting the Electrical Properties of Tumor Biology in Pancreatic Cancer

MEQUON, Wis., May 1, 2026 /PRNewswire/ -- (TSXV: PAIN) — Vector Science & Therapeutics, (the "Company") today announced the filing of a provisional patent application covering a novel catheter-based platform designed for intratumoral drug delivery research, with an initial scientific focus on pancreatic cancer. The filing initiates a preclinical research program exploring the integration of three delivery and activation modalities in a disease where the scientific rationale for localized, targeted intervention is well established and the unmet need remains significant.

Pancreatic cancer represents one of oncology's most studied and persistent unmet needs. Approximately 80% of patients are diagnosed at a locally advanced or metastatic stage (National Cancer Institute/NCI), where surgery is not feasible. Despite available systemic regimens, five-year survival rates remain below 5% for this population (NCI), and the literature reflects sustained scientific interest in localized delivery strategies as a complement to or alternative to systemic approaches. Vector's provisional patent describes a platform architecture intended to advance that area of research.

The platform integrates three research modalities: intratumoral delivery of cell differentiation agents, electrical ablation based on the differential conductivity of tumor tissue, and electrically-guided chemotherapy activation.

> *"Each of the three modalities in this platform has a basis in the existing literature. The integration is novel. Our work now is to build the preclinical evidence that will determine whether that integration delivers what the science suggests is possible."*

— Tom Bachinski, Chief Technology Officer, Vector Science & Therapeutics

The provisional patent filing establishes and protects the intellectual property position as preclinical work begins. The Company's immediate focus is on proof-of-principle validation: generating the foundational data required to assess feasibility, refine the system architecture, and support future regulatory and clinical collaboration. No preclinical or clinical data have yet been generated or published for this specific platform.

ABOUT VECTOR SCIENCE & THERAPEUTICS

Vector Science & Therapeutics Corp., headquartered in Mequon, Wisconsin, develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The Company's shares are listed on the TSX Venture Exchange under the symbol PAIN. For more information, visit www.vectorscience.co.

Forward-Looking Statements

Investor Relations: Bill Jackson, Chief Executive Officer, Vector Science & Therapeutics, bill@vectorscience.co